SB939
A substance being studied in the treatment of several types of cancer. SB939 blocks the action of an enzyme called histone deacetylase (HDAC) and may stop tumor cells from dividing. It is a type of HDAC inhibitor.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.